<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03057431</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01475</org_study_id>
    <nct_id>NCT03057431</nct_id>
  </id_info>
  <brief_title>Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis</brief_title>
  <acronym>NOSTONE</acronym>
  <official_title>Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to assess the efficacy of standard and low dose HCTZ treatment in the
      recurrence prevention of calcium-containing kidney stones. More specifically, the
      investigators aim to assess the dose-response relationship for three different dosages of
      HCTZ.

      Study intervention: HCTZ 12.5 mg, 25 mg or 50 mg once daily per os for 24 or 36 months. In
      addition, all patients in HCTZ treatment arms will receive state-of-the-art non-pharmacologic
      recommendations for stone prevention according to current guidelines.

      Control intervention: Placebo once daily per os for 24 to 36 months. In addition, all
      patients in the placebo arm will receive state-of-the-art non-pharmacologic recommendations
      for stone prevention according to current guidelines.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men
      and 9.4% in women. Without specific treatment, 5- and 20-year recurrence rates are 40% and
      75%, respectively. Given the high cost of medical treatments and surgical interventions as
      well as the morbidity related to symptomatic stone disease, medical prophylaxis for stone
      recurrence is an attractive approach.

      About 80-90% of stones are composed of calcium oxalate with various admixtures of calcium
      phosphate. Increased excretion of calcium in the urine, hypercalciuria, is the most common
      metabolic abnormality encountered in patients with recurrent nephrolithiasis. Thiazide
      diuretics have been the cornerstone of pharmacologic metaphylaxis for more than 40 years. The
      effect of thiazides to reduce the risk of stone recurrence has been attributed to their
      ability to decrease urinary calcium excretion. However, other factors, such as reduction of
      urinary pH and urinary oxalate excretion, probably contribute to this effect. Efficacy of
      thiazides on recurrence prevention of calcareous nephrolithiasis was tested in 11 randomized
      controlled trials (RCTs). With the exception of two trials, thiazides significantly reduced
      stone recurrence. Most of these trials are from the 1980's and 90's and the cumulative number
      of patients studied is remarkably low for such a prevalent disease. Our systematic review of
      these RCTs revealed major methodological deficiencies in all trials, including: lack of
      double-blinding and intention-to-treat analysis, unclear allocation concealment, lack of
      adverse event and drop out reporting and unknown baseline risk of disease severity.
      Furthermore, high doses of thiazides were employed in all trials, in the case of the best
      studied thiazide, hydrochlorothiazide (HCTZ), up to 100 mg daily. At such high doses, side
      effects occur frequently. Nowadays, thiazides are widely used in the treatment of recurrent
      nephrolithiasis and arterial hypertension, but at significantly lower doses. In the case of
      recurrent nephrolithiasis, however, this practice is not supported by randomized evidence and
      consequently, the investigators do not know whether the currently employed low dose thiazide
      regimens are effective in reducing the risk for stone recurrence.

      Thus, evidence for benefits and harms of thiazide diuretics in the prevention of
      calcium-containing kidney stones in general remains unclear. In addition, the efficacy of the
      currently employed low dose thiazide regimens to prevent stone recurrence is not known.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
    <description>Composite of symptomatic or radiological recurrences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of symptomatic stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of radiologic stone recurrences</measure>
    <time_frame>After 3 years</time_frame>
    <description>Measured by low-dose CT</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">416</enrollment>
  <condition>Nephrolithiasis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.5 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25.0 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50.0 mg hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>12.5 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25.0 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>25.0 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50.0 mg hydrochlorothiazide</intervention_name>
    <description>Once daily for 3 years</description>
    <arm_group_label>50.0 mg hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed Consent as documented by signature

          2. Age 18 years or older

          3. Recurrent kidney stone disease (â‰¥ 2 stone events within the last 10 years prior to
             randomization)

          4. Any past kidney stone containing 50% or more of calcium oxalate, calcium phosphate or
             a mixture of both

        Exclusion Criteria:

          1. Pharmacologic prevention for stone recurrence less than 3 months prior to
             randomization

          2. Patients with secondary causes of recurrent calcareous nephrolithiasis including:

               -  Severe eating disorders (anorexia or bulimia)

               -  Chronic inflammatory bowel disease, bariatric surgery, intestinal surgery with
                  malabsorption or chronic diarrheal status

               -  Sarcoidosis

               -  Primary hyperparathyroidism

               -  Complete distal tubular acidosis

               -  Active malignancy

          3. Patients with the following medications:

               -  Thiazide or loop diuretics

               -  Carbonic anhydrase inhibitors (including topiramate)

               -  Xanthine oxidase inhibitors (febuxostat or allopurinol)

               -  Alkali, including potassium citrate or sodium bicarbonate

               -  Treatment with 1,25-OH Vitamin D (calcitriol)

               -  Calcium supplementation

               -  Bisphosphonates

               -  Denosumab

               -  Teriparatide

               -  Glucocorticoids

          4. Obstructive uropathy, if not treated successfully

          5. Urinary tract infection, if not treated successfully

          6. Chronic kidney disease (defined as CKD-EPI eGFR &lt; 30 mL/min per 1,73 m2 body surface
             area for more than 3 months)

          7. Patients with a kidney transplant

          8. &gt; 3 gout arthritis episodes within one year prior to randomisation or gout arthritis
             requiring uric acid lowering therapy

          9. Cystinuria at screening

         10. Hypokalemia (blood potassium level &lt; 3 mmol/L) at screening

         11. Hyponatremia (blood sodium level &lt; 125 mmol/L) at screening

         12. Pregnant and lactating women [pregnancy test to be performed for women of
             child-bearing potential (defined as women who are not surgically sterilized/
             hysterectomized, and/ or who are postmenopausal for less than 12 months)]

         13. Previous (within 3 months prior to randomization) or concomitant participation in
             another interventional clinical trial

         14. Inability to understand and follow the protocol

         15. Known allergy to the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Fuster, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology and Hypertension, Bern University Hospital, Bern, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Fuster, Prof MD</last_name>
    <phone>+41 (0)31 632 31 44</phone>
    <email>daniel.fuster@insel.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luca TamÃ², PhD</last_name>
    <phone>+41 (0)31 631 30 87</phone>
    <email>luca.tamo@ctu.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Buchkremer, MD</last_name>
      <email>florian.buchkremer@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mayr, MD</last_name>
      <email>michael.mayr@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Bellinzona e Valli (San Giovanni)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Gabutti, Prof MD</last_name>
      <email>luca.gabutti@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital (Inselspital)</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Fuster, Prof MD</last_name>
      <email>daniel.fuster@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital GraubÃ¼nden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reto Venzin, MD</last_name>
      <email>Reto.Venzin@ksgr.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pitaux universitaires de GenÃ¨ve (HUG)</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ernandez, MD</last_name>
      <email>thomas.ernandez@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Bonny, Prof MD-PhD</last_name>
      <email>olivier.bonny@unil.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano (Civico)</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo SchÃ¶nholzer, MD</last_name>
      <email>carlo.schoenholzer@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urs Odermatt, MD</last_name>
      <email>urs.odermatt@luks.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Teta, Prof MD-PhD</last_name>
      <email>daniel.teta@hopitalvs.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St.Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Koneth, MD</last_name>
      <email>irene.koneth@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital ZÃ¼rich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Ritter, MD</last_name>
      <email>alexander.ritter@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>kidney stones</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

